Parkinson’s disease (PD) is the second most common neurodegenerative disorder, entailing several motor-related symptoms that contribute to a reduced quality of life in affected subjects. Recent advances in wearable technologies and computing resources have shown great potential for the assessment of PD-related symptoms. However, the potential applications (e.g., early diagnosis, prognosis and monitoring) and key features of digital biomarkers for motor symptoms of PD (DB-MS-PD) have not been comprehensively studied. This study aims to provide a state-of-the-art review of current digital biomarker definitions for PD, focusing on the use of wearable devices. This review systematically examines research articles from 2012 to 2024, focusing on key features and recent technologies in PD research. A total of 22 studies were included and thoroughly analyzed. Results indicate that DB-MS-PD can accurately distinguish patients with PD (PwPD) from healthy controls (HC), assess disease severity or treatment response, and detect motor symptoms. Large sample sizes, proper validation, non-invasive devices, and ecological monitoring make DB-MS-PD promising for improving PD management. Challenges include sample and method heterogeneity and lack of public datasets. Future studies can leverage evidence of the current literature to provide more effective and ready-to-use digital tools for monitoring PD.
Introduction: Parkinson’s disease (PD) is a neurodegenerative disorder commonly characterized by motor impairments. The development of mobile health (m-health) technologies, such as wearable and smart devices, presents an opportunity for the implementation of clinical tools that can support tasks such as early diagnosis and objective quantification of symptoms.Objective: This study evaluates a framework to monitor motor symptoms of PD patients based on the performance of standardized exercises such as those performed during clinic evaluation. To implement this framework, an m-health tool named Monipar was developed that uses off-the-shelf smart devices.Methods: An experimental protocol was conducted with the participation of 21 early-stage PD patients and 7 healthy controls who used Monipar installed in off-the-shelf smartwatches and smartphones. Movement data collected using the built-in acceleration sensors were used to extract relevant digital indicators (features). These indicators were then compared with clinical evaluations performed using the MDS-UPDRS scale.Results: The results showed moderate to strong (significant) correlations between the clinical evaluations (MDS-UPDRS scale) and features extracted from the movement data used to assess resting tremor (i.e., the standard deviation of the time series: r = 0.772, p < 0.001) and data from the pronation and supination movements (i.e., power in the band of 1–4 Hz: r = −0.662, p < 0.001).Conclusion: These results suggest that the proposed framework could be used as a complementary tool for the evaluation of motor symptoms in early-stage PD patients, providing a feasible and cost-effective solution for remote and ambulatory monitoring of specific motor symptoms such as resting tremor or bradykinesia.
Background: Monitoring motor symptoms in patients with Parkinson disease (PD) presents significant challenges due to the complex nature of symptom progression, variations in medication responses, and the fluctuations that can occur throughout the day. Traditional neurological visits provide only a limited perspective of a patient’s overall condition, with challenges in achieving accurate and objective assessments of symptoms. To bridge this gap, extended monitoring in nonclinical settings could play a critical role in personalizing treatments and improving their efficacy. Wearable devices have emerged as potential tools for assessing PD symptom severity; however, studies integrating both in-clinic and free-living conditions, as well as multiday monitoring, remain scarce. Defining digital biomarkers that provide valuable insights into motor symptoms could enable comprehensive monitoring and tracking of PD in various contexts, facilitating more precise medication adjustments and the implementation of advanced therapeutic strategies. Objective: This study aims to collect a dataset to support the proposal and definition of digital biomarkers of PD motor symptoms using wearable devices. Data will be collected both in a supervised setting and continuously in a remote, free-living context during participants’ normal daily activities; the study will include patients with PD and healthy controls. The goal is to identify reliable digital biomarkers that can effectively distinguish patients with PD from healthy controls and classify disease severity in both supervised and unsupervised free-living environments. Methods: This paper outlines a protocol for an observational case-control study aimed at assessing motor symptoms in patients with PD using a smartwatch. The smartwatch will record accelerometer, gyroscope, and physical activity data. Participants will be instructed to perform a series of exercises guided via a smartphone. Measurements will be collected in 2 settings: a supervised clinical environment, with motor symptoms assessments conducted at the beginning and end of the study, and in an unsupervised free-living context for 1 week. In both settings, participants will be required to wear the smartwatch while performing the same set of exercises. In their daily routine, participants will be required to wear the smartwatch continuously throughout the day, removing it only at night for charging. Results: Participant recruitment and data collection started in December 2024 and will continue until spring 2025. The study aims to enroll 20 participants with PD and 20 healthy controls. Conclusions: It is anticipated that the generation of a dataset of accelerometer and gyroscope signal data recorded from patients with PD at various stages of the disease, alongside data from a control group, will enable robust comparative and impactful analyses. In addition, the study seeks to develop analytical techniques capable of tracking PD symptoms in real-life scenarios, both in everyday settings and clinical environments. Trial Registration: ClinicalTrials.gov NCT06817772; https://clinicaltrials.gov/study/NCT06817772 International Registered Report Identifier (IRRID): DERR1-10.2196/72820
Parkinson's disease (PD) is the second most common neurodegenerative disorder, entailing several motor-related symptoms that contribute to a reduced quality of life in affected subjects. Recent advances in wearable technologies and computing resources have shown great potential for the assessment of PD-related symptoms. However, the potential applications (e.g., early diagnosis, prognosis and monitoring) and key features of digital biomarkers for motor symptoms of PD (DB-MS-PD) have not been comprehensively studied. This study aims to provide a state-of-the-art review of current digital biomarker definitions for PD, focusing on the use of wearable devices. This review systematically examines research articles from 2012 to 2024, focusing on key features and recent technologies in PD research. A total of 22 studies were included and thoroughly analyzed. Results indicate that DB-MS-PD can accurately distinguish patients with PD (PwPD) from healthy controls (HC), assess disease severity or treatment response, and detect motor symptoms. Large sample sizes, proper validation, non-invasive devices, and ecological monitoring make DB-MS-PD promising for improving PD management. Challenges include sample and method heterogeneity and lack of public datasets. Future studies can leverage evidence of the current literature to provide more effective and ready-to-use digital tools for monitoring PD.